机械论文英文文摘

本资料包含pdf文件1个，下载需要5积分

英文文摘New classes of antibacterial agents with novel mechan-
isms of action are urgently needed to combat the
increase in multidrug resistant infections. Recent reports
indicate that in 1998， at least 21% of all nosocomial
enterococcal infections in US hospitals were due to
vancomycin-resistant enterococci (VRE).
1
The oxazoli-
dinones， a new class of totally synthetic antibacterial
agents， are active against a variety of clinically impor-
tant susceptible and resistant Gram-positive organisms
such as methicillin-resistant Staphylococcus aureus
(MRSA)， VRE， and penicillin-resistant Streptococcus
pneumoniae (PRSP). Scientists at DuPont originally
discovered this class of agents in the late 1980s.
2
However， development of DuP-721， the drug candidate
that emerged from these initial studies， was dis-
continued following Phase I clinical trials. Subse-
quently， researchers at Pharmacia and Upjohn
identified two clinical candidates， eperezolid (1) and
linezolid (2).
3
Linezolid is currently marketed for the
treatment of multidrug resistant Gram-positive infec-
tions such as nosocomial and community-acquired
pneumonia and skin infections.